secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0000899923-23-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q1 revenue $181.2M (+10% YoY); raises FY23 revenue guidance midpoint
--------------------------------------------------------------------------------

- Q1 GAAP EPS $(0.67); adjusted EPS $(0.21); revenue $181.2M (+10% YoY).
- Testing volumes +21% ex-SneakPeek; hereditary cancer +24%, GeneSight +31% YoY.
- FY23 revenue guidance raised to $730-750M (previous $720-750M); gross margin 68-70% reaffirmed.
- GAAP gross margin 67.3% (down 360bps YoY) due to product mix and $12.4M prior-year benefit.
- Ended Q1 with $109.1M cash, no debt; management targets profitability by Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/0000899923-23-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/mygn-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer